Novartis
Novartis,
Novartis'
hits
has
had
have
acquisition
acquisitions
acquisitions.
acquisition,"
acquired
announced
and
analysts
all
also
affiliate
after
able
about
as
adding
are
trail
trading.
to
told
the
there
their
them
they
that
than
those
Swiss
Sandoz
Sandoz,
Sal
drug
drugmaker
drugmakers
drugs
deal
deal.
departments,
development
do
5.65bn
57.85
euros
each.
early
estimated.
expected
expensive
expires
exactly
($7.4bn;
Â£3.9bn)
of
offered
overtake
on
outlook
purchases
producer
producer.
products
protection
predicted
pressure."
price
partially
patent
pay
make
maker
making
may
market
markets
month
more
merge
merged
it
its
in
initially
investment
is
identical
unit
usually
world's
worldwide
work
would
which
where
will
were
biggest
bought
buy
business
be
branded
bank,
generic
generics.
growth
last
for
forecast
force,"
following
francs
fragmented.
from
figures
firm
find
record
remaining
reductions
research
rose
rivals.
sales
said
savings
shares
see
sell
strong
strange
statement.
such
suffered
2005,
2004
Germany's
Generic
Hexal.
Hexal's
However,
It
Israel's
67.7%
US
Eon
Labs,
$31
$200m
$5bn,
cost
cost.
company
compensate
copy
consolidation
convinced
cuts.
create
chemically
cheaply
can
call
year
1%
150
The
There
Teva
Pharmaceuticals
Producers
Based
Birgit
newly
necessary
number
not
job
jobs,
"The
"This
"I
very
Kuhlhoff,
Oppenheim
Reuters.